Top advances in lung cancer, 2021.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35947027.
- Also identified by DOI 10.1002/cncr.34406 and PMC identifier 9886158.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first-in-class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung cancer. LAY SUMMARY: There has been tremendous innovation in the treatment of nonsmall cell lung cancer. The year 2021 was marked by new approaches to adjuvant therapy and the availability of agents to target new subsets of nonsmall cell lung cancer.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms